CAMBRIDGE, England--(BUSINESS WIRE)--Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as ...

Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to end the morbidity and mortality of aging, today announced the release of new research detailing an ...

Investment led by BGF, with support from existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner Seed funding will accelerate development of Shift Bioscience’s platform for ...

Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for age driven diseases, today announced the results of a new study detailing an ...

Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council Sir Tony Kouzarides, Co-founder and Director, Milner Therapeutics ...

Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals ...

CAMBRIDGE, England, November 11, 2025--(BUSINESS WIRE)--Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to end the morbidity and mortality of aging, today ...

Shift Bioscience is building a cell simulation platform that combines generative AI with its highly accurate, high-throughput biological aging clock, to predict which sets of genes are most likely to ...

AI virtual cells outperform key baselines on well-calibrated metrics, challenging prior reports of poor model performance Foundational research reinforces the use of virtual cell models to accelerate ...